Cytori Provides Business Update and Reports Third Quarter and Nine Month 2012 Results

Cytori Provides Business Update and Reports Third Quarter and Nine Month 2012 Results

SAN DIEGO--(BUSINESS WIRE)-- During the third quarter and first nine months of 2012, Cytori Therapeutics (NAS: CYTX) advanced its cardiac cell therapy pipeline and achieved important strategic commercial and regulatory milestones. Additionally, Cytori reaffirmed its $9 million revenue guidance for the year. The Company accomplished the following objectives since the end of the second quarter:


  • Awarded a U.S. Government contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Department of Health and Human Services. The contract is valued at up to $106 million and will be used to develop Cytori's cell therapy for the treatment of thermal burns combined with radiation injury. Contract activities are currently underway including the initiation of key proof of concept studies in addition to accelerating development of the next generation Celution® system.

Clinical Pipeline

  • Initiated enrollment in ATHENA, the U.S. clinical trial of Cytori's cell therapy for refractory heart failure; the trial is on track to fully enroll by mid-2013.
  • Resumed enrollment in ADVANCE, a European acute myocardial infarction trial; primary emphasis of the trial continues to be completion of country and site clearances.

Commercial Business

  • Expanded Japanese market access in the third quarter by obtaining a full commercial operational license for Cytori Therapeutics K.K. and Class 1 medical device clearance for the Celution® and Puregraft® based technologies. In combination, these resulted in the highest gross quarterly product shipments to date.
  • Expanded Celution® CE Mark certification to include indications-for-use in wound healing and tissue ischemia.

Operations & Financial Performance

  • Reduced net cash used in operating activities in the first nine months of 2012 compared to the first nine months of 2011, driven by reductions in sales, general and administrative expenses.

"This quarter we made significant progress on both the clinical and commercial fronts which will help drive our growth in 2013 and beyond," said Christopher J. Calhoun, chief executive officer for Cytori Therapeutics. "Throughout the rest of the year and into 2013, we will look to continue to expand enrollment in our ongoing clinical trials, achieve additional strategic partnerships and secure more approvals that drive revenue growth."

Financial Results

Product revenues were $1.3 million and $4.7 million for the third quarter and first nine months of 2012, respectively, compared with $2.1 million and $5.9 million for the same periods in 2011. Additionally, based on the receipt of the Japan commercial operational license and Class 1 device clearance late in the third quarter of 2012, Cytori shipped an additional $1.7 million of systems and consumables that we expect to recognize as product revenue in a subsequent quarter. Cytori reaffirms its $9 million revenue guidance for 2012 based on already achieved shipments and anticipated orders.

Gross profit was $0.6 million and $2.2 million for the third quarter and first nine months of 2012, compared to $1.2 million and $3.0 million for the same periods of 2011, respectively.

Research and development expenses increased to $3.6 million and $9.6 million for the third quarter and first nine months of 2012, compared to $2.8 million and $8.9 million, the same periods respectively in 2011. This planned increase is principally associated with the emergence of the ATHENA trial. In contrast, sales, general and administrative expenses were reduced to $6.2 million and $18.9 million in the third quarter and first nine months of 2012, a decrease of 13% compared to both the third quarter of 2011 ($7.2 million) and the first nine months of 2011 ($21.8 million) respectively.

Net cash used in operating activities for the third quarter of 2012 was $7.9 million compared to $7.9 million for the same period in 2011 and $8.2 million in the second quarter of 2012. Net loss was $11.2 million, or ($0.19) per share, and $28.5 million, or ($0.49) per share, for the third quarter and first nine months of 2012, respectively. This compares to $8.3 million, or ($0.15) per share, and $25.5 million, or ($0.48) per share for the third quarter and first nine months of 2011, respectively. Net loss for the third quarter and first nine months of 2012 includes a net non-cash charge of $1.2 million and $1.7 million respectively related to the change in the fair value of warrant and option liabilities compared to non-cash credit of $1.0 million and $3.0 million for the same periods, respectively in 2011.

At the end of the third quarter of 2012, Cytori had $17.6 million of cash and cash equivalents and $3.2 million of accounts receivable and expected revenue from the additional product shipments in the third quarter.

Management Conference Call Webcast and Shareholder Letter Information

Cytori will host a management conference call at 5:00 p.m. Eastern Time today to further discuss the company's progress. The webcast will be available live and by replay two hours after the call and may be accessed under "Webcasts" in the Investor Relations section ( of Cytori's website. If you are unable to access the webcast, you may dial in to the call at +1.877.402.3914, Conference ID: 42763342. More details on our business are contained in the 'November 2012 Shareholder Letter' posted on the homepage of our Investor Relations website.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position, such as our expectation of completion of enrollment of the ATHENA clinical trial by mid-2013, and our revenue guidance of $9 million for the year. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, such as those associated with the ATHENA clinical trial, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.



As of September 30, 2012As of December 31, 2011
Current assets:
Cash and cash equivalents$17,628,000$36,922,000
Accounts receivable, net of reserves of $455,000 and of $474,000 in 2012 and 2011, respectively1,463,0002,260,000
Inventories, net3,411,0003,318,000
Other current assets 1,090,000 837,000
Total current assets23,592,00043,337,000
Property and equipment, net2,242,0001,711,000
Restricted cash and cash equivalents350,000350,000
Investment in joint venture122,000250,000
Other assets1,756,0001,772,000
Intangibles, net26,000192,000
Goodwill 3,922,000 3,922,000
Total assets$32,010,000$51,534,000
Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses$5,588,000$5,334,000
Current portion of long-term obligations 9,767,000 2,487,000
Total current liabilities15,355,0007,821,000
Deferred revenues, related party1,107,0003,520,000
Deferred revenues5,147,0005,244,000
Warrant liability1,871,000627,000
Option liability2,400,0001,910,000
Long-term deferred rent684,000504,000
Long-term obligations, net of discount, less current portion 15,178,000 21,962,000
Total liabilities41,742,00041,588,000
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011
Common stock, $0.001 par value; 95,000,000 shares authorized; 58,720,627 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively59,00057,000
Additional paid-in capital261,113,000252,338,000
Accumulated deficit (270,904,000) (242,449,000)
Total stockholders' equity (deficit) (9,732,000) 9,946,000
Total liabilities and stockholders' equity (deficit)$32,010,000$51,534,000
For the Three Months

Ended September 30,

For the Nine Months

Ended September 30,

2012 20112012 2011
Product revenues$ 1,314,000$ 2,134,000$ 4,741,000$ 5,908,000
Cost of product revenues703,000942,0002,588,0002,893,000
Gross profit611,0001,192,0002,153,0003,015,000
Development revenues:
Development, related party2,413,0001,231,000
Research grant and other2,0005,00021,00019,000
Operating expenses:
Research and development3,555,0002,830,0009,615,0008,948,000
Sales and marketing2,450,0003,618,0007,406,00010,560,000
General and administrative3,777,0003,538,00011,489,00011,230,000
Change in fair value of warrant liability863,000(1,536,000)1,244,000(3,714,000)
Change in fair value of option liability300,000570,000490,000680,000
Total operating expenses10,945,0009,020,00030,244,00027,704,000
Operating loss(10,332,000)(7,823,000)(25,657,000)(23,439,000)
Other income (expense):
Interest income3,0003,0007,000
Interest expense(857,000)(489,000)(2,582,000)(1,923,000)
Other income (expense), net(17,000)25,000(91,000)(36,000)
Equity loss from investment in joint venture(42,000)(51,000)(128,000)(153,000)
Total other income (expense)(916,000)(512,000)(2,798,000)(2,105,000)
Net loss$ (11,248,000)$ (8,335,000)$ (28,455,000)$ (25,544,000)
Basic and diluted net loss per common share$ (0.19)$ (0.15)$ (0.49)$ (0.48)
Basic and diluted weighted average common shares58,713,03653,900,25058,292,91152,775,861
For the Nine Months Ended September 30,
 2012  2011
Cash flows from operating activities:
Net loss$(28,455,000)$(25,544,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization712,000621,000
Amortization of deferred financing costs and debt discount706,000471,000
Provision for doubtful accounts99,000274,000
Change in fair value of warrant liability1,244,000(3,714,000)
Change in fair value of option liability490,000680,000
Share-based compensation expense2,907,0002,578,000
Equity loss from investment in joint venture128,000153,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable698,000(168,000)
Other current assets(253,000)132,000
Other assets16,000(764,000)
Accounts payable and accrued expenses254,000(396,000)
Deferred revenues, related party(2,413,000)(1,231,000)
Deferred revenues(97,000)189,000
Long-term deferred rent 180,000 70,000
Net cash used in operating activities (23,877,000) (27,424,000)
Cash flows from investing activities:
Purchases of property and equipment (1,077,000) (458,000)
Net cash used in investing activities (1,077,000)
Read Full Story
Scroll to continue with content AD
  • DJI26816.59319.891.21%
    S&P 5002970.2732.141.09%
  • NIKKEI 22521798.87246.871.15%
    Hang Seng26545.24236.800.90%
  • USD (PER EUR)1.10-0.0011-0.10%
    USD (PER CHF)1.000.00060.06%
    JPY (PER USD)108.26-0.1000-0.09%
    GBP (PER USD)1.26-0.0044-0.35%
More to Explore